SPAC Merger Update: Extension Payment Breaches, Debt Forgiveness, and Nasdaq Delisting Risk Emerge at Black Hawk
BKHA sits 17% above its 52-week low of $10.09 on elevated volume (2.9× avg).
Summary
Black Hawk's S-4/A discloses that it breached extension payment cure periods in late 2025, which should have forced liquidation, but the board continued the Vesicor merger. Vesicor forgave $1M+ in advances, and the company faces Nasdaq delisting risk.
Key Events · M&A and Partnerships · BKHA
-
Extension Payment Breaches
Black Hawk failed to timely make November and December 2025 extension payments within the 45-day cure periods, which under its charter should have triggered liquidation. The board decided not to liquidate, acknowledging potential legal claims.
-
Debt Forgiveness Agreement
On June 30, 2026, Vesicor forgave $1,015,987.50 in advances previously made to Black Hawk, including $675,000 in extension payments and $340,987.50 in transaction expenses.
-
Nasdaq Delisting Risk
Black Hawk received a Nasdaq notice on March 31, 2026, that its market value of listed securities fell below the $50M minimum. It has until September 28, 2026, to regain compliance.
-
NTA Requirement Removal Proposed
A new proposal seeks to remove the $5,000,001 net tangible asset requirement, which could allow the merger to close even with very low cash reserves, increasing post-merger financial risk.
Analysis · BKHA · Life Sciences
The latest S-4/A from Black Hawk reveals that it missed cure periods for two monthly extension payments in late 2025, a breach that under its charter should have triggered liquidation. Instead, the board opted to press ahead with the Vesicor merger, while acknowledging potential legal claims. In a separate development, Vesicor forgave over $1 million in advances. The filing also introduces a proposal to eliminate the net tangible asset requirement, warns of a Nasdaq delisting notice, and updates pro forma financials. Together, these disclosures materially heighten the risk profile of the pending de-SPAC transaction.
At the time of this filing, BKHA was trading at $11.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.9M. The 52-week trading range was $10.09 to $13.10. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.